CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The
Technology, Healthcare and Hospitals, Health
2025-11-10 11:37 PM EST | CardioComm Solutions, Inc.
LevelJump Announces 2025 Third Quarter Results
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce its financial results for the three months and nine months ended September 30, 2025. Financial and Operational Highlights Revenues were $4.84 million in the third quarter compared to $4.45 million in the same period the prior year, an increase of 8.7%. For the nine months ended S
Healthcare and Hospitals, Health
2025-11-10 10:31 PM EST | LevelJump Healthcare Corp.
Game-Changing Alliance: Adia Labs and Axia
Winter Park, Florida--(Newsfile Corp. - November 10, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today announced a strategic partnership between its research and development division, Adia Labs, and AxiaMD, a premier provider of nationwide physician oversight and compliance services for med spas, IV clinics, physician assistants, nurse practitioners, and wellness practices. Under the agreement, AxiaMD's extensive network
Healthcare and Hospitals, Health
2025-11-10 9:00 AM EST | Adia Nutrition Inc.
Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026
Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025. Total Revenues - Net increased by 4% to $26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier. Income from Operations decreased 30% to $3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.
Technology, Healthcare and Hospitals
2025-11-10 8:00 AM EST | Fonar Corporation
Envoy Medical Reports Third Quarter 2025 Financial and Operational Results
White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced its corporate and financial results for the third quarter ended September 30, 2025, as well as other subsequent events. Corporate Highlights for Third Quarter 2025:
Biotechnology, Healthcare and Hospitals
2025-11-10 8:00 AM EST | Envoy Medical, Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating re
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-10 7:00 AM EST | Elite Pharmaceuticals, Inc.
Theralase(R) Releases 3Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 3Q2025 financial statements ("Financial Statements"). Theralase® will be host
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-10 7:00 AM EST | Theralase Technologies Inc.
LevelJump Announces Receipt of Notice of Requisition for a Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - November 7, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") announces that a notice of requisition of a meeting of shareholders (the "Requisition") was delivered to the registered office of the Company on November 3, 2025. The Requisition has been made by Frank Teti and Franmar Properties Ltd. (collectively the "Concerned Shareholders") which requires that the Company call and hold a meeting of shareholders pursuant to s
Healthcare and Hospitals, Health
2025-11-07 5:00 PM EST | LevelJump Healthcare Corp.
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.
James Anderson Provides Update on Holdings of Myndtec Inc.
Detroit, Michigan--(Newsfile Corp. - November 6, 2025) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On November 4, 2025, the Issuer completed the seventh tranche (the "Seventh Tranche") of a private placement of units ("Units") announced on January 30, 2025. 262,027 Units
Technology, Healthcare and Hospitals, Health
2025-11-06 4:30 PM EST | James Anderson
HEALWELL Achieves Record Q3 Revenue Growth Now as a Pure-Play Global SaaS, Services & AI Company for Health Systems and Life Sciences
HEALWELL achieved quarterly revenue from continuing operations of $30.4 million in Q3-2025, an increase of 354% compared to revenue of $6.7 million generated in Q3-2024. Revenue growth in the quarter was largely driven by the Orion Health acquisition. During Q3-2025, HEALWELL reported positive Adjusted EBITDA of $0.7 million, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024. This marks the Company's second consecutive quarter of
Technology, Healthcare and Hospitals
2025-11-06 8:04 AM EST | HEALWELL AI
AmeriHealth Caritas Builds on Year of Action to Address Food Insecurity
Newtown Square, Pennsylvania--(Newsfile Corp. - November 5, 2025) - AmeriHealth Caritas today announced new contributions to support Feeding America® in helping families access nutritious food. The combined $350,000 from AmeriHealth Caritas, and the AmeriHealth Caritas Foundation, reflects an ongoing commitment to addressing food insecurity as part of its mi
2025-11-05 12:13 PM EST | AmeriHealth Caritas
Adia Nutrition Inc. Announces Transformative 2025 Milestones and Strategic Progress Toward Nasdaq Uplisting
Winter Park, Florida--(Newsfile Corp. - November 5, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and premium wellness solutions, today recaps its pivotal year-to-date achievements, marked by explosive revenue growth, strategic divestitures, and decisive steps toward full SEC reporting and a Nasdaq listing. 2025 Key Milestones Q3 Revenue Surges Over 200% Quarter-Over-Quarter: On October 8, preliminary results sh
Healthcare and Hospitals, Health
2025-11-05 10:00 AM EST | Adia Nutrition Inc.
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Reno, Nevada--(Newsfile Corp. - November 5, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, today announced the appointments of Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors. The additions bring together leading expertise from the worlds of medicine, science, and ethics-driven innovation as Conexeu advances its mission to pioneer collagen-based
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-05 7:00 AM EST | Conexeu Sciences Inc.
MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - November 4, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the seventh tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The seventh tranche of the private placement consists of 262,027 Units of the Company (the "Units") at a price of
Technology, Healthcare and Hospitals, Health
2025-11-04 6:00 PM EST | MyndTec Inc.
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-04 5:30 PM EST | Medexus Pharmaceuticals Inc.
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the first three patients have been enrolled in the final stage of the Company's pivotal clinical trial of the full implanted Acclaim® cochlear implant. These initial surgeries in this final stage were performed by Dr. Abraham Jacob at the Center for Neurosciences
Biotechnology, Healthcare and Hospitals
2025-11-04 8:00 AM EST | Envoy Medical, Inc.
Wellgistics Health Enters into LOI to Acquire Kare Rx Hub
Tampa, Florida--(Newsfile Corp. - November 4, 2025) - We
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-11-04 6:00 AM EST | Wellgistics Health
CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform
Toronto, Ontario--(Newsfile Corp. - November 4, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has terminated a royalty agreement announced October 1, 2025 (the "Royalty Agreement) and entered into a loan agreement dated November 3, 2025 (the "Loan Agreement") with current debt lenders to the Company (the "Lend
Technology, Healthcare and Hospitals, Health
2025-11-04 12:40 AM EST | CardioComm Solutions, Inc.